FGFR3-related dwarfism and cell signaling

Journal of Bone and Mineral Metabolism

Volumn 27, Issue 1, 2009, Pages 9-15

  Harada, Daisuke ^a   Yamanaka, Yoshitaka ^a   Ueda, Koso ^b   Tanaka, Hiroyuki ^c   Seino, Yoshiki ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d OSAKA KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Cell signaling; Clinical therapy; Dwarfism; Fibroblast growth factor receptor 3

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

BONE GROWTH; DWARFISM; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE MUTATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

BODY PATTERNING; BONE DEVELOPMENT; DWARFISM; HUMANS; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 58149178539     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-008-0009-7     Document Type: Review

References (74)

1. A Superti-Furga L Bonafe DL Rimoin 2001 Molecular-pathogenetic classification of genetic disorders of the skeleton Am J Med Genet 106 4 282 293
2. CM Hall 2002 International nosology and classification of constitutional disorder of bone (2001) Am J Med Genet 113 1 65 77
3. U Kornak S Mundlos 2003 Genetic disorders of the skeleton: a developmental approach Am J Hum Genet 73 3 447 474
4. R Shiang LM Thompson YZ Zhu DM Church TJ Fielder M Bocian ST Winokur JJ Wasmuth 1994 Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia Cell 78 335 342
5. F Rousseau J Bonaventure L Legeai-Mallet A Pelet JM Rozet P Marotearx MM Le A Munnich 1994 Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia Nature (Lond) 371 252 254
6. GA Bellus I McIntosh EA Smith AS Aylsworth I Kaitila WA Horton GA Greenhaw JT Hecht CA Francomano 1995 A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia Nat Genet 10 3 357 359
7. GA Bellus PW Speiser CA Weaver AT Garber CR Bryke J Israel SS Rosengren MK Webster DJ Donoghue CA Francomano 2000 Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype Am J Hum Genet 67 1411 1421
8. PL Tavormina R Ahiang LM Thompson YZ Zhu DJ Wilkin RS Lachman WR Wilcox DL Rimoin DH Cohn JJ Wasmuth 1995 Thanatophoric dysplasia (type I and type II) caused by distinct mutations in fibroblast growth factor receptor 3 Nat Genet 9 321 328
9. PL Tavormina DL Rimon DH Cohn YZ Zhu R Shiang JJ Wamuth 1995 Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I Hum Mol Genet 4 2175 2177
10. F Rousseau P Saugier M LeMerrer A Munnich AL Delezoide P Moroteaux J Bonaventure F Narcy M Sanak 1995 Stop codon FGFR3 mutation in thanatophoric dwarfism type I Nat Genet 10 11 12
11. PL Tavormina GA Bellus MK Webster MJ Bamshad AE Fraley I Mclntosh J Szabo W Jiang EW Jabs WR Wilcox JJ Wasmuth DJ Donoghue LM Thompson CA Francomano 1999 A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene Am J Hum Genet 64 722 731
12. C Deng A Wynshaw-Boris F Zhou A Kuo P Leder 1996 Fibroblast growth factor receptor 3 is a negative regulator of bone growth Cell 84 911 921
13. NB Weksler GP Lunstrum ES Reid WA Horton 1999 Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro Biochem J 342 pt 3 677 682
14. F De Luca J Baron 1999 Control of bone growth by fibroblast growth factors Trends Endocrinol Metab 10 2 61 65
15. L Legeai-Mallet C Benoist-Lasselin A Munnich J Bonaventure 2004 Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias Bone (NY) 34 1 26 36
16. JS Colvin BA Bohne GW Harding DG McEwen DM Ornitz 1996 Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 Nat Genet 12 4 390 397
17. MW Pantoliano RA Horlick BA Springer DE Van Dyk T Tobery DR Wetmore JD Lear AT Nahapetian JD Bradley WP Sisk 1994 Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization Biochemistry 33 34 10229 10248
18. E Shi M Kan J Xu F Wang J Hou WL McKeehan 1993 Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants Mol Cell Biol 13 7 3907 3918
19. K Peters D Ornitz S Werner L Williams 1993 Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis Dev Biol 155 2 423 430
20. SE Hughes 1997 Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues J Histochem Cytochem 45 7 1005 1019
21. Z Vajo CA Francomano DJ Wilkin 2000 The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans Endocr Rev 21 1 23 39
22. K Kannan D Givol 2000 FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models IUBMB Life 49 3 197 205
23. Rousseau F, Bonaventure J, Legeai-Mallet L, Pelet A, Rozet JM, Maroteaux P, Le Merrer M, Munnich A (1996) Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia. Horm Res 45(1-2):108-110
24. GA Bellus I McIntosh EA Smith AS Aylsworth I Kaitila WA Horton GA Greenhaw JT Hecht CA Francomano 1995 A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia Nat Genet 10 3 357 359
25. G Grigelioniene L Hagenas O Eklof L Neumeyer PE Haereid M Anvret 1998 A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online Hum Mutat 11 4 333
26. GA Bellus EB Spector PW Speiser CA Weaver AT Garber CR Bryke J Israel SS Rosengren MK Webster DJ Donoghue CA Francomano 2000 Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype Am J Hum Genet 67 6 1411 1421
27. A Winterpacht K Hilbert C Stelzer T Schweikardt H Decker H Segerer J Spranger B Zabel 2000 A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia Physiol Genomics 2 1 9 12
28. SG Brodie H Kitoh RS Lachman LM Nolasco PB Mekikian WR Wilcox 1999 Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations Am J Med Genet 84 5 476 480
29. PL Tavormina R Shiang LM Thompson YZ Zhu DJ Wilkin RS Lachman WR Wilcox DL Rimoin DH Cohn JJ Wasmuth 1995 Thanatophoric dysplasia (type I and type II) caused by distinct mutations in fibroblast growth factor receptor 3 Nat Genet 9 321 328
30. PL Tavormina DL Rimoin DH Cohn YZ Zhu R Shiang JJ Wasmuth 1995 Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I Hum Mol Genet 4 2175 2177
31. F Rousseau P Saugier M Le Merrer A Munnich AL Delezoide P Maroteaux J Bonaventure F Narcy M Sanak 1995 Stop codon FGFR3 mutation in thanatophoric dwarfism type I Nat Genet 10 11 12
32. MK Webster PY D'Avis SC Robertson DJ Donoghue 1996 Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II Mol Cell Biol 16 8 4081 4087
33. PL Tavormina GA Bellus MK Webster MJ Bamshad AE Fraley I McIntosh J Szabo W Jiang EW Jabs WR Wilcox JJ Wasmuth DJ Donoghue LM Thompson CA Francomano 1999 Novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene Am J Hum Genet 64 722 731
34. GA Bellus MJ Bamshad KA Przylepa J Dorst RR Lee O Hurko EW Jabs CJ Curry WR Wilcox RS Lachman DL Rimoin CA Francomano 1999 Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3 Am J Med Genet 85 1 53 65
35. WH McAlister JP Crane RP Bucy RB Craig 1985 A new neonatal short limbed dwarfism Skeletal Radiol 13 4 271 275
36. LO Langer Jr PA Baumann RJ Gorlin 1967 Achondroplasia Am J Roentgenol 100 12 26
37. JT Hecht NM Thompson T Weir L Patchell WA Horton 1991 Cognitive and motor skills in achondroplastic infants: neurologic and respiratory correlates Am J Hum Genet 41 208 211
38. MM Cohen Jr GF Walker C Phillips 1985 Morphometric analysis of the craniofacial configuration in achondroplasia J Craniofac Genet Dev Biol 1 139 165
39. F Rousseau J Bonaventure L Logeai-Mallet H Schmidt J Wessenbach P Maroteaux A Munnich M Le Merrer 1996 Clinical and genetical heterogeneity of hypochondroplasia J Med Genet 33 749 752
40. U Ramaswami G Rumsby PC Hindmarsh CGD Brook 1998 Genotype and phenotype in hypochondroplasia J Pediatr 133 99 102
41. JM Connor RAC Connor EM Sweet AAM Gibson WJA Patrick MB McNay DHA Redford 1985 Lethal neonatal chondrodysplasias in the West of Scotland, 1970-1983, with a description of a thanatophoric, dysplasia like, autosomal recessive disorder, Glasgow variant Am J Med Genet 22 243 253
42. ML Martinez-Frias MA Ramos-Arroyo J Salvador 1988 Thanatophoric dysplasia: an autosomal dominant condition? Am J Med Genet 31 815 820
43. BR Elejalde MM de Elejalde 1985 Thanatophoric dysplasia: fetal manifestations and prenatal diagnosis Am J Med Genet 22 4 669 683
44. LO Langer Jr SS Yang JG Hall A Sommer SR Kottamasu M Golabi N Krassikoff 1987 Thanatophoric dysplasia and cloverleaf skull Am J Med Genet Suppl 3 167 179
45. AM Norman S Rimmer S Landy D Donnai 1992 Thanatophoric dysplasia of the straight-bone type (type 2) Clin Dysmorph 1 115 120
46. A Giedion 1968 Thanatophoric dwarfism Helv Paediat Acta 23 175 183
47. GA Bellus MJ Bamshad KA Przylepa J Dorst RR Lee L Hurko EW Jabs CJ Curry WR Wilcox RS Lachman DL Rimoin CA Francomano 1999 Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3 Am J Med Genet 85 1 53 65
48. MC Naski Q Wang J Xu DM Ornitz 1996 Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia Nat Genet 13 233 237
49. PM Lievens E Liboi 2003 The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum J Biol Chem 278 19 17344 17349
50. PMJ Lievens C Mutinelli D Daynes E Liboi 2004 The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling J Biol Chem 279 41 43254 43260
51. D Harada Y Yamanaka K Ueda R Nishimura T Morishima Y Seino H Tanaka 2007 Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLC-gamma-activated STAT1 Bone (NY) 41 2 273 281
52. MK Webster DJ Donoghue 1996 Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia EMBO J 15 3 520 527
53. DM Ornitz PJ Marie 2002 FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease Genes Dev 16 12 1446 1465
54. VP Eswarakumar I Lax J Schlessinger 2005 Cellular signaling by fibroblast growth factor receptors Cytokine Growth Factor Rev 16 2 139 149
55. CG L'Hote MA Knowles 2005 Cell responses to FGFR3 signalling: growth, differentiation and apoptosis Exp Cell Res 304 2 417 431
56. WA Horton JG Hall JT Hacht 2007 Achondroplasia Lancet 370 162 172
57. KC Hart SC Robertson DJ Donoghue 2001 Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation Mol Biol Cell 22 931 942
58. M Koike Y Yamanaka M Inoue H Tanaka R Nishimura Y Seino 2003 Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK J Bone Miner Res 18 2043 2051
59. A Yasoda Y Komatsu H Chusho T Miyazawa A Ozasa M Miura T Kurihara T Rogi S Tanaka M Suda N Tamura Y Ogawa K Nakao 2004 Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway Nat Med 10 1 80 86
60. MC Naski JS Colvin JD Coffin DM Ornitz 1998 Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3 Development (Camb) 125 4977 4988
61. Y Yamanaka H Tanaka M Koike R Nishimura Y Seino 2003 PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation J Bone Miner Res 18 1395 1403
62. H Tanaka T Kubo T Yamate T Ono S Kanzaki Y Seino 1998 Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype Eur J Endocrinol 138 3 275 280
63. U Ramaswami PC Hindmarsh CG Brook 1999 Growth hormone therapy in hypochondroplasia Acta Paediatr Suppl 88 428 116 117
64. Y Yamanaka Y Seino M Shinohara S Ikegami M Koike M Miyazawa M Inoue T Moriwake H Tanaka 2000 Growth hormone therapy in achondroplasia Horm Res 53 suppl 3 53 56
65. H Kanazawa H Tanaka M Inoue Y Yamanaka N Namba Y Seino 2003 Efficacy of growth hormone therapy for patients with skeletal dysplasia J Bone Miner Metab 21 5 307 310
66. N Yasui H Kawabata H Kojimoto H Ohno S Matsuda N Araki Y Shimomura T Ochi 1997 Lengthening of the lower limbs in patients with achondroplasia and hypochondroplasia Clin Orthop Relat Res 344 298 306
67. R Aldegheri C Dall'Oca 2001 Limb lengthening in short stature patients J Pediatr Orthop B 10 3 238 247
68. D Aviezer M Golembo A Yayon 2003 Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia: genetic short limbed dwarfism Curr Drug Targets 4 5 353 365
69. K Ueda Y Yamanaka D Harada E Yamagami H Tanaka Y Seino 2007 PTH has the potential to rescue disturbed bone growth in achondroplasia Bone (NY) 41 1 13 18
70. H Hagiwara H Sakaguchi M Itakura T Yoshimoto M Furuya S Tanaka S Hirose 1994 Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B J Biol Chem 269 14 10729 10733
71. CF Bartels H Bukulmez P Padayatti DK Rhee C van Ravenswaaij-Arts RM Pauli S Mundlos D Chitayat L-Y Shih LI Al-Gazali S Kant T Cole J Morton V Cormier-Daire L Faivre M Lees J Kirk GR Mortier J Leroy B Zabel CA Kim Y Crow NE Braverman F van den Akker ML Warman 2004 Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux Am J Hum Genet 75 27 34
72. LR Potter S Abbey-Hosch DM Dickey 2006 Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions Endocr Rev 27 47 72
73. R Rauchenberger E Borges E Thomassen-Wolf E Rom R Adar Y Yaniv M Malka I Chumakov S Kotzer D Resnitzky A Knappik S Reiffert J Prassler K Jury D Waldherr S Bauer T Kretzschmar A Yayon C Rothe 2003 Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3 J Biol Chem 38 38194 38205
74. D Aviezer M Golembo A Yayon 2003 Fibroblast growth factor receptor-3 as a therapeutic target for achondroplasia: genetic short limbed dwarfism Curr Drug Targets 4 5 353 365